Analysis of the activities of the clinical pharmacy service in the use of vancomycin in a public hospital in Belo Horizonte

Authors

DOI:

https://doi.org/10.30968/rbfhss.2024.152.1157

Abstract

Objective: To characterize the population in vancomycin use, and analyze the parameters of indication, effectiveness and safety used by clinical pharmacists in the drug utilization review. Method: This is a cross-sectional study with retrospective collection of medical records of patients who used intravenous vancomycin from March 2022 to March 2023. The results of therapeutic monitoring of vancomycin and pharmaceutical interventions related to this antibacterial were evaluated. Results: The study included 919 patients with 1026 hospital admissions. The mean age of the population was 56.8±17.9 years and 50.9% were older than 60 years. In the period evaluated, 9379 vancomycin prescriptions were identified. The most prevalent reason for vancomycin prescription was “others: cite in observation” (15.1%), followed by “respiratory infection - nosocomial pneumonia” (14.8%). The care line responsible for most of the vancomycin prescriptions (42.9%) were the intensive care. Only 23.5% of the serum vancomycin trough concentrations results were in the range considered ideal, i.e. 15-20mg/L. Among the results that were outside the reference range, 38.2% were supratherapeutic (≥20.1mg/L) and 18.7% were subtherapeutic (≤9.9mg/L). In the drug utilization review led by pharmacists, 190 interventions were performed with the medical team. The therapeutic monitoring of vancomycin was the most prevalent intervention (44.7%) of which 87.1% were accepted. Conclusion: The study showed a high rate of serum vancomycin trough concentrations results outside the therapeutic range (76.5%) indicating the need to strengthen the institutional protocol and clinical staff training. The clinical pharmacist had an important role in identifying this risk by performing drug utilization review and therapeutic monitoring of vancomycin.

Downloads

Download data is not yet available.

References

Agência Nacional de Vigilância Sanitária. Projeto Stewardship Brasil. Avaliação Nacional dos Programas de Gerenciamento do Uso de Antimicrobianos em Unidade de Terapia Intensiva Adulto dos Hospitais Brasileiros. 2019. Disponível em: https://antigo.anvisa.gov.br/documents/33852/271855/Projeto+Stewardship+Brasil/435012dc-4709-4796-ba78-a-0235895d901?version=1.0. Acessado em: 10 abr 2023.

Ministério da Saúde. Plano de Ação Nacional de Prevenção e Controle da Resistência Aos Antimicrobianos No Âmbito da Saúde Única 2018–2022. 2019. Disponível em: https://bvsms.saude.gov.br/bvs/publicacoes/plano_prevencao_resistencia_antimicrobianos.pdf. Acessado em: 10 abr 2023.

Doron S, Davidson LE. Antimicrobial stewardship. Mayo Clin Proc. 2011;86(11):1113-23. DOI: 10.4065/mcp.2011.0358.

Agência Nacional de Vigilância Sanitária. Diretriz Nacional para Elaboração de Programa de Gerenciamento de Antimicrobianos em Serviços de Saúde. 2023. Disponível em: https://www.gov.br/anvisa/pt-br/centraisdeconteudo/publicacoes/servicosdesaude/publicacoes/DiretrizGerenciamentoAntimicrobianosANVISA2023FINAL.pdf. Acessado em: 13 jan 2024.

Krukas A, Franklin ES, Bonk C, et al. Identifying Safety Hazards Associated With Intravenous Vancomycin Through the Analysis of Patient Safety Event Reports. Patient Safety. 2020;2(1):31-47. DOI:10.33940/data/2020.3.3

Dombroski V, Da Silva MMG, Silveira ME. Monitoramento terapêutico de vancomicina em uma unidade de terapia intensiva. Rev. Med. UFPR. 2015;2(2):67-73. DOI: 10.5380/rmu.v2i2.42233.

Van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother. 2013;57(2):734-44. DOI: 10.1128/AAC.01568-12.

Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society Of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66:82-98. DOI 10.2146/ajhp080434.

Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020;77(11):835-864. DOI: 10.1093/ajhp/zxaa036.

Williams, P.G., Tabah, A., Cotta, M.O. et al. International survey of antibiotic dosing and monitoring in adult intensive care units. Crit Care. 2023;27(1):241. DOI: 10.1186/s13054-023-04527-1.

Phillips CJ, Gordon DL. Pharmacist-led implementation of a vancomycin guideline across medical and surgical units: impact on clinical behavior and therapeutic drug monitoring outcomes. Integr Pharm Res Pract. 2015;4:145-152. DOI: 10.2147/IPRP.S92850.

Leitão CL, Medeiros AF, Dias EF, et al. Inteligência artificial no serviço farmacêutico de análise de prescrições médicas em um hospital público. Rev Bras Farm Hosp Serv Saude. 2023;14(3):991. DOI: 10.30968/rbfhss.2023.143.0991.

Medeiros AF, Bertollo CM, Reis AMM, et al. Building an antimicrobial stewardship program: A narrative of six years under the Donabedian perspective. Front. Pharmacol. 2023;14:1074389. DOI: 10.3389/fphar.2023.1074389.

Jeffres M N. The whole price of vancomycin: toxicities, troughs, and time. Drugs. 2017;77(11):1143-1154. DOI: 10.1007/s40265-017-0764-7.

Conselho Federal de Farmácia. Resolução n° 585 de 29 de agosto de 2013. Regulamenta as atribuições clínicas do farmacêutico e dá outras providências. Disponível em: https://www.cff.org.br/userfiles/file/resolucoes/585.pdf. Acessado em: 1° out. 2023.

Momattin H, Zogheib M, Homoud A, et al. Safety and outcome of pharmacy-led vancomycin dosing and monitoring. Chemotherapy. 2016;61(1):3-7. DOI: 10.1159/000440607.

Guay DR, Vance-Bryan K, Gilliland S, et al. Comparison of vancomycin pharmacokinetics in hospitalized elderly and young patients using a Bayesian forecaster. J Clin Pharmacol. 1993;33(10):918-22. DOI: 10.1002/j.1552-4604.1993.tb01922.x.

Infectious Diseases Society of America. Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children. 2011.

Pritchard L, Baker C, Leggett J, et al. Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity. Am J Med. 2010;123(12):1143-1149. DOI: 10.1016/j.amjmed.2010.07.025.

Marquis KA, DeGrado JR, Labonville S, et al. Evaluation of a pharmacist-directed vancomycin dosing and monitoring pilot program at a tertiary academic medical center. Ann Pharmacother. 2015;49(9):1009-14. DOI: 10.1177/1060028015587900.

Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61-e111. DOI: 10.1093/cid/ciw353.

Ochotorena E, Morante JJH, Cañavate R, et al. Methicillin-resistant Staphylococcus aureus and other multidrug-resistant colonizations/infections in an intensive care unit: predictive factors. Biol Res Nurs. 2019;21(2):190-197. DOI: 10.1177/1099800418818387.

Blot S, Ruppé E, Harbarth S, et al. Healthcare-associated infections in adult intensive care unit patients: Changes in epidemiology, diagnosis, prevention and contributions of new technologies. Intensive Crit Care Nurs. 2022;70:103227. DOI: 10.1016/j.iccn.2022.103227.

Van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother. 2013;57(2):734-44. DOI: 10.1128/AAC.01568-12.

Esprendor RF, Silva GT, Banhuk FW, et al. Impact of the pharmacist’s request for vancomycin dosage in a university hospital: observational study. Rev Bras Farm Hosp Serv Saude. 2023;14(1):0819. DOI: 10.30968/rbfhss.2023.141.0819.

Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302(21):2323-2329. DOI: 10.1001/jama.2009.1754.

De almeida CDC, E Silva ACS, Oliveira JAQ, et al. Vancomycin-associated nephrotoxicity in non-critically ill patients admitted in a Brazilian public hospital: A prospective cohort study. PLoS One. 2019;14(9):e0222095. DOI: 10.1371/journal.pone.0222095.

Conselho Federal de Farmácia. Monitorização terapêutica de medicamentos. Contextualização e Arcabouço Conceitual. 2022. Disponível em: https://admin.cff.org.br/src/uploads/publicacao/arquivo/954b6b8068bbdb7fc685366d4d95c38d-8058dc0b.pdf. Acessado em: 09 nov 2023.

Published

2024-06-30

How to Cite

1.
AUGUSTO AC, MEDEIROS AF, MARTINS MA, LEITÃO CL, BRANDÃO MC, DIAS EF, BERTOLLO CM. Analysis of the activities of the clinical pharmacy service in the use of vancomycin in a public hospital in Belo Horizonte. Rev Bras Farm Hosp Serv Saude [Internet]. 2024Jun.30 [cited 2024Jul.20];15(2):e1157. Available from: https://rbfhss.org.br/sbrafh/article/view/1157

Issue

Section

ORIGINAL ARTICLES